Swemed Sense™ approved for sales in Australia

Vitrolife has received approval from TGA (Therapeutic Goods Administration) for its new needle for the collection of human oocytes, Swemed Sense™ (patent pending), which reduces the risk of tissue damage and pain. It will be launched in Australia in October.

“Swemed Sense™, with its unique characteristics, is an important part of our existing product portfolio in Europe, and is now available even to our Australian customers, Says Vitrolife's Vice President of Marketing and Sales, Nils Sellbom. Vitrolife have identified Australia as one of the key markets in the world and we have a office located in Melbourne. Approximately 67 000 fertility treatment cycles are conducted in Australia and New Zealand each year” The Swemed Sense™ oocyte aspiration needle is designed with a thinner front part and tip so as to minimize tissue damage, bleeding and pain. However, the rear part of the needle has a larger diameter. This makes the needle stable and therefore does not reduce the handling ability. Furthermore, the procedure is just as fast as when a thicker needle is used, which is not the case with uniformly thin needles. A patent application has been submitted for Swemed Sense™ in all major markets. September 28, 2009 Göteborg, Sweden Magnus Nilsson CEO Queries should be addressed to: Magnus Nilsson, CEO, phone +46 31 721 80 61 Eva Nilsagård, CFO, phone +46 31 721 80 13

About Us

Vitrolife is an international medical device Group. The Fertility product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. Vitrolife has approximately 330 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Mid Cap.

Subscribe

Documents & Links